How Small/Mid-Size Firms are Shaping the Healthcare M&A Market

Dr Fintan Walton founded PharmaVentures, a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

Over a period of three decades, Fintan has built PharmaVentures into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have also included major banks, investment/merchant banks, as well as private equity and venture capital groups.

Dr Walton majored in Genetics at Trinity College Dublin, Ireland, where he also gained a Ph.D. Prior to his entrepreneurial activities at PharmaVentures, Fintan had built his R&D and commercial experience in biotechnology within management positions at Bass and Celltech plc (1982-1992).

In 1996, he also founded PharmaDeals, the leading database and publishing business related to dealmaking data and analytics. Thousands of customers from around the world either bought or subscribed to these PharmaDeals publications. The PharmaDeals business was sold to IMS Health (now IQVIA) in Aug 2012.

Jonathan is the Head of Corporate Business Development at Bio-Rad. Previously, he was the Head of Corporate & Business Development at Illumina.

Earlier in his career, he led Strategy and Business Development for the Life Sciences Division at Becton, Dickinson and Diagnostics Business Development at Roche Diagnostics in both the US and Switzerland. He studied Medicine, Molecular Biology and Finance degrees at universities in Great Britain.

Paul has over 25 years’ experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Paul has expertise in capital raising, business development, technology commercialisation and sales & marketing globally. Paul has launched products using both in-house and outsourced sales staff in Australia and the US. He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Paul has previously served as Chairman, Director or Managing Director/CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies.

Paul Chairs the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC. He is an expert advisor to PharmaVentures (Oxford, UK) and Mind Medicine. Paul also serves on a number of other NFP and government advisory groups and has recently provided advice to both DESE and DISER related to pandemic responses.

Paul graduated with a Bachelor of Veterinary Science from the University of Sydney. In addition, Paul completed a Grad Cert Eng Woolongong, a Grad Dip Eng (Tech Mgt) Swinburne and a Master of Business Administration degree at Macquarie University.

Adrian is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian led multiple consultancy, licensing and M&A mandates. Notable deals include licensing transactions between MedGenesis and Pfizer, Esteve and Mundipharma, and M&A for a UK diagnostics business with Bruker and the sale of NanoSight to Spectris plc.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. He has held senior positions with Johnson & Johnson, drug discovery platform company Acumen Bioscience and the Healthcare Consultancy company Execute Technologies. Adrian has over 30 years in the pharmaceutical, biotechnology and in vitro diagnostics sectors.

Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

Jansen is a healthcare transactions professional with over 27 years in the life science sector with expertise in M&A, licensing, strategy and commercial DD. With considerable experience in the pharma services sector, Jansen has and taken key roles in many M&A mandates including the divestment of multiple sites for clients such as Novartis, Sanofi, Merck and UCB. Over the years he has also worked on a range of assignments including licensing, valuation and strategy projects.

Jansen holds a PhD in Biochemistry from the University of Sussex and an MBA from Oxford Brookes University.